Objectives: To study the antiproliferative effects of ER119884 and E5700, two quinuclidine-based inhibitors of squalene synthase (SQS), against Toxoplasma gondii tachyzoites in epithelial cells.
Introduction
Toxoplasma gondii is the aetiological agent of toxoplasmosis, a widespread disease worldwide. Toxoplasmosis affects principally immunocompromised individuals and newborns with congenital disease. The clinical manifestations of congenital toxoplasmosis include hydrocephalus, chorioretinitis and blindness. 1, 2 Toxoplasmosis in immunocompromised individuals can be the result of the reactivation of chronic (latent) infection. 3 The presence of the parasite in the CNS causes necrotizing encephalitis and in AIDS patients it is the main cause of focal cerebral lesions. 4, 5 In immunocompetent individuals the disease is unnoticed in most of the patients, becoming latent with the formation of cysts principally in the CNS.
The mainstays of toxoplasmosis chemotherapy are antifolate drugs, such as the combination of pyrimethamine and sulfadiazine. Although this therapy is frequently successful, it is associated with many side effects including bone marrow suppression, minimized by concomitant administration of folinic acid. 6 However, sometimes the discontinuation of antifolate treatment is necessary and in cases of immunocompromised individuals the disease can be life-threatening requiring replacement therapy with another regimen. The sulfa component is also frequently not well tolerated, requiring its substitution by other drugs such as clindamycin. 7 Therefore, the development of alternative single or combination therapies is necessary.
Sterol biosynthesis inhibitors (SBIs) azasterols have already been demonstrated to have a selective effect on T. gondii proliferation, when used alone and in combination with antifolates. 8, 9 A new class of SBIs, squalene synthase (SQS) inhibitors, has been tested, showing promising anti-trypanosomatid activity in vitro and in vivo. [10] [11] [12] [13] In this work we evaluated two quinuclidines, 
Materials and methods

Parasites and host cells
Tachyzoites from the virulent RH strain of T. gondii were used in this study and were maintained by intraperitoneal passages in Swiss mice. After 48 h of infection the parasites were collected in phosphatebuffered saline (PBS) at pH 7.2. The ascitic fluid obtained from infected mice was centrifuged at 200 g for 10 min at room temperature to remove cells and debris. The supernatant, which contained the parasites, was collected and centrifuged at 1000 g for 10 min. The pellet obtained was washed with PBS at pH 7.2 and then in RPMI medium without fetal bovine serum (FBS). The parasites were used within 30-40 min of their removal from the peritoneal cavity. The experimental protocol was approved by the Instituto de Biofísica Carlos Chagas Filho (Universidade Federal do Rio de Janeiro) Ethics Committee for animal experimentation. LLCMK2 cell cultures (kidney, Rhesus monkey, Macaca mulata) were maintained in RPMI medium with 5% FBS at 37 C in an atmosphere of 5% CO 2 . The viability of the parasite and host cell during the experiments was determined as described previously. 14 For in vitro studies these compounds were dissolved in dimethyl sulfoxide (DMSO) and added directly to the growth medium; the final concentration of DMSO in the medium never exceeded 0.1% (v/ v) and had no effect on the proliferation of intracellular parasites and host cells. Sulfadiazine (Sigma Chemical Co.) was dissolved in sterile distilled water and pyrimethamine (Sigma Chemical Co.) was dissolved in absolute ethanol. All the drugs were stored at 4 C.
Antiproliferative assays
Approximately 2 · 10 4 LLCMK2 cells/well were placed in a 24-well tissue culture plate 2 days before the assay. The cells were infected with freshly obtained parasites and resuspended in RPMI without FBS at a multiplicity of 3:1 parasite/host cell. Tachyzoites were allowed to interact for 1 h and then the cell monolayers were washed twice with PBS to remove non-adherent extracellular parasites. The drugs were added to the infected cells after 6 h of interaction. After treatment, samples were fixed with Bouin, stained with Giemsa and observed in a light microscope. The percentage of infected cells and the parasite proliferation index were determined by examination of at least 400 cells of two different coverslips. Data shown are representative of three experiments. The parasite proliferation index was determined by multiplying the percentage of infected cells by the total number of intracellular parasites per total number of cells. 15 
Effect of the drugs on the ultrastructure of T. gondii-infected cells
For these experiments LLCMK2 cultures were infected with parasites at a multiplicity of 5. The control and drug-treated cells were fixed with 2.5% glutaraldehyde in 0.1 M sodium cacodylate buffer (pH 7.4). Cells were post-fixed for 1 h in the dark with a solution containing 1% osmium tetroxide, 0.8% potassium ferrocyanide and 5 mM CaCl 2 , in 0.1 M sodium cacodylate buffer (pH 7.4). Dehydration was carried out with acetone; samples were embedded in PolyBed (Polyscience Inc.). Ultrathin sections were stained with uranyl acetate and lead citrate and observed in a Jeol 1200 electron microscope.
Synergy calculations
EIL (0.05-1.0 mM) and sulfadiazine/pyrimethamine (0.1 mM/0.4 nM to 100 mM/0.4 mM) alone or in combination with (i) ER119884 (0.05 and 0.1 mM) or (ii) E5700 (0.02 and 0.04 mM) were added to infected monolayers and incubated with the cells for 48 h. Synergy is defined as an effect produced by a combination of components that is greater than the sum of the effects produced by the components alone. Classical isobolograms were constructed by plotting concentrations of drugs that alone or in combination induced 50% inhibition of tachyzoites growth (IC 50 ) after 48 h. According to accepted guidelines FICI values were interpreted as follows: £0.5, synergism; >0.5-4, no interaction; and >4, antagonism. 17 
Statistical analysis
The results were analysed by applying two-way analysis of variance (ANOVA) and P values were considered statistically significant at <0.05.
Results and discussion
Antiproliferative effects of quinuclidine derivatives
The drugs added after 6 h of infection in LLCMK2 cell cultures were capable of reducing T. gondii tachyzoite proliferation in a dose-dependent manner (Figures 1 and 2) . The IC 50 values were 0.66 -0.1 and 0.44 -0.08 mM for ER119884 and 0.23 -0.06 and 0.19 -0.03 mM for E5700 after 24 and 48 h of interaction, respectively. We also tested the antiproliferative effects after different times (1-24 h) of infection: both drugs maintained their antiproliferative activity even 12 h post-infection. When the drugs were added after 24 h, reductions of 58% and 48% were observed with 3 mM E5700 and ER119884, respectively, demonstrating that the drugs could efficiently reduce parasite burdens after the infection is fully established (Figure 3) . However, if the drugs at the same concentrations were added 6 h postinfection and removed from the growth medium after 42 h of incubation, it was found that the parasites began to grow normally, showing that at this concentration the drugs had a static rather than cidal effect or that there was a remaining subpopulation of parasites not affected by the treatment under these conditions.
The IC 50 values of the two quinuclidines derivatives observed in this work against T. gondii were somewhat higher than those previously reported against Trypanosoma cruzi, 12 but in both studies the compounds were active at submicromolar levels and E5700 was the most active one.
The results obtained, although preliminary, demonstrated that the novel quinuclidine derivatives have antiproliferative activity against T. gondii at lower concentrations than those of the standard drugs, sulfadiazine and pyrimethamine (IC 50 16.4/0.067 mM after 48 h), under identical experimental conditions.
Despite the fact that quinuclidine derivatives inhibit mammalian SQS, 12, [18] [19] [20] [21] [22] [23] the treatment with these drugs did not provoke any alteration in the morphology or loss of viability (data not shown) in host cells submitted to concentrations five times higher than the maximum concentration used during parasite antiproliferative tests. As discussed elsewhere, 12 this fact is probably explained by the capacity of the host cells to compensate for the blockade of de novo cholesterol synthesis by up-regulating the expression of low-density lipoprotein (LDL) receptors and taking this sterol from the growth medium. The drugs were demonstrated to be well tolerated by mice in in vivo tests. 12 Although the quinuclidine derivatives had excellent effects against T. gondii at submicromolar levels, the mechanism of action is still unclear. A search in the T. gondii database (www.toxodb.org) demonstrated the absence of SQS from the parasite genome. Besides, as described before, T. gondii is auxotrophic for cholesterol, acquiring this molecule from the host cell LDL-receptor pathway. 24 
Ultrastructure alterations induced by quinuclidine derivatives
Electron microscopy analysis demonstrated many alterations in the ultrastructure of tachyzoites treated with quinuclidine derivatives. In contrast with untreated parasites (Figure 4a ), tachyzoites treated with 3 mM ER119884 displayed an abnormal vacuolization of the parasite cytoplasm, mitochondrial swelling, disrupted cristae and the appearance of autophagosome-like structures after 24 h (Figure 4b and c) . The presence of lamellar bodies in the parasitophorous vacuole was continuously observed (data not shown). However, when the infected cells were treated with 3 mM E5700 more remarkable effects were observed after 24 h of treatment: the parasites were seen with portions of their pellicle, a system composed of a plasma membrane unit and an inner membrane complex composed of two lipid bilayers, disarranged (Figure 4d ). This effect could be caused by an alteration in the physicochemical properties of this membrane system, making it more susceptible to disruption. Mitochondrial swelling and the presence of whorls of membrane profiles in vacuoles were also visualized (Figure 4d-f) . The enlargement of Golgi complex cisternae (data not shown) and complete cytoplasm disorganization could frequently be observed in T. gondii treated with both drugs. Treatment of infected cells with quinuclidine derivatives did not seem to affect the parasitophorous vacuole membrane. The ultrastructural alterations did not pinpoint any specific primary site of action of the drugs in T. gondii, although effects on membranes of cellular structures appear even in shortest times of treatment. It is likely that components of parasite membranes are being affected. Therefore a biochemical investigation of the neutral and polar lipid profiles is currently underway by our group in order to determine the possible molecular target. 
Effects of quinuclidine derivatives in combination with EIL
EIL is a known inhibitor of D 24 (25) sterol methyl transferase (SMT). The antiproliferative effects of this compound against T. gondii tachyzoites and other protozoan parasites have been demonstrated in previous studies. 8, 9, 25, 26 In the present study we sought to verify the anti-T. gondii activity of quinuclidine derivatives in combination with EIL.
EIL alone inhibited parasite growth with an IC 50 of 0.36 -0.10 mM. When the SMT inhibitor was combined with 0.1 mM ER119884 the EIL IC 50 was reduced to 0.132 -0.028 mM, producing a slightly concave isobologram, with an FICI of 0.59 -0.08, indicating the absence of interaction between these drugs ( Figure 5, left-hand panel) . The association with 0.04 mM E5700 was able to reduce the IC 50 of EIL from 0.36 to 0.091 -0.023 mM; this drug combination produced a fully concave isobologram, with an FICI of 0.46 -0.06, demonstrating synergic effects ( Figure 5, right-hand panel) . The molecular mechanism of EIL, as for quinuclidines derivatives, is still unknown, but the results obtained here show that these drugs possibly affect different molecular targets, otherwise a synergic effect would not be observed.
Effect of the association of quinuclidine derivatives and antifolates
The effects of the combination of ER119884 and E5700 with antifolates were also studied. The IC 50 obtained for sulfadiazine/ pyrimethamine was 16.4 -4.2 mM for sulfadiazine and 0.067 -0.016 mM for pyrimethamine after 48 h of treatment. The association of quinuclidine derivatives with sulfadiazine/pyrimethamine induced a remarkable enhancement of their antiproliferative activities; both compounds acted synergically with antifolates. The IC 50 of sulfadiazine/pyrimethamine decreased to 3.24 -0.36 mM/12.87 -1.43 nM with the addition of 0.04 mM E5700, with an FICI of 0.34 -0.09 ( Figure 6 , left-hand panel). The presence of 0.1 mM ER119884 reduced the sulfadiazine/pyrimethamine IC 50 to 3.3 -0.13 mM/13.19 -0.52 nM, with an FICI of 0.43 -0.01 ( Figure 6 , right-hand panel). These results are similar to those reported previously for the association of EIL with sulfadiazine/pyrimethamine 9 and suggest the possibility of lowering the antifolate doses when used in combination with novel drugs, such as SBIs, thus reducing the side effects associated with this therapy without loss of efficacy.
